Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an eye drop cure Hard-to-Heal leg sores?

NCT ID NCT02422017

Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a beta-blocker eye drop called timolol, applied directly to the wound, can help heal venous leg ulcers that have not improved with standard care. Forty-two adults with ulcers lasting at least 24 weeks received either timolol plus standard wound care or standard care alone for 12 weeks. The goal was to see if timolol could shrink the ulcer by at least 40% or lead to complete healing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
timolol (a beta-blocker eye drop applied directly to the ulcer)
What this could lead to
If it works, this could offer a simple, low-cost way to help stubborn venous leg ulcers heal faster.
What could go wrong
This is a small Phase 2 trial with only 42 people, so results may not apply to everyone. Timolol is a beta-blocker and could cause heart-related side effects when absorbed through the skin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

42 people

The number who actually took part.

Start date

Apr 2015

Finished

Jan 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Affiliated to a social security scheme patients * Informed consent * Patients over 18 years * Ulcer lasting for at least 24 weeks with no improvement observed after 4 weeks of well conducted treatment (compression and local care) * Presence of one or more venous leg ulcers (objectified by a Doppler ultrasound dated within 6 months and ABPI ≥ 0.8) * Ulcers with a surface of 5 to 50 cm ² and at granulation stage * Study ulcer must be at least 2 cm from Any Other ulcer on same extremity. * If several ulcers present, the greatest is selected * Granulation tissue ≥ 50% Exclusion Criteria: * Minors under guardianship, deprived of liberty, not looking at treatment, lack of signed consent, pregnant women, demented patients * Ulcer lasting for less than 24 weeks * Granulation tissue \<50% * Obliterative arteritis (ABPI \<0.8) * Infection of the ulcer (need to treat the infection before any inclusion criteria be compatible) * Non-cardioselective beta-blocker treatment * Bradycardiac treatment * Patients under diltiazem, verapamil (calcium antagonists) * Reaching underlying noble structures, tumor acutisation wound * Immunosuppression * Diabetes unbalanced (HbA1c\> 8%) * Severe Malnutrition (albumin \<25g / L) * Anemia \<10g/dl * Contraindication to beta-blockers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous leg ulcers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

injury Leg Ulcer ulcer of lower limbs

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous leg ulcers

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.